Charles Schwab
IKT icon

Charles Schwab’s Inhibikase Therapeutics IKT Stock Holding History

Charles Schwab’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$558K Buy
275,041
+39,627
+17% +$70.9K ﹤0.01% 3211
2026
Q1 		$395K Buy
235,414
+83,116
+55% +$148K ﹤0.01% 3177
2025
Q4 		$312K Hold
152,298
– – ﹤0.01% 3269
2025
Q3 		$247K Hold
152,298
– – ﹤0.01% 3329
2025
Q2 		$297K Buy
+152,298
New +$298K ﹤0.01% 3313

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's IKT Position: Q2 2026 in Review

Charles Schwab increased its Inhibikase Therapeutics (IKT) stake by 17% in Q2 2026, buying an estimated $70.9K and bringing the position to 275,041 shares worth $558K. The position accounts for ﹤0.01% of the portfolio, ranked #3211.

Charles Schwab first reported a position in IKT in Q2 2025 and has held it in 5 quarters since. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Charles Schwab held 275,041 shares of Inhibikase Therapeutics worth $558K as of Q2 2026.
  • Charles Schwab bought 39,627 Inhibikase Therapeutics shares in Q2 2026, an estimated $70.9K.
  • Inhibikase Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3211 holding.
  • Charles Schwab first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.